Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine

Medicine

Florence Roufosse¹  Joseph Butterfield²  Jonathan Steinfeld³  Namhee Kwon⁴  Linda Nelsen⁵  Robyn von Maltzahn⁶  Jane H. Bentley⁶ 

[1] Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium;Division of Allergic Diseases and the Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, MN, United States;Respiratory Research & Development, GSK, Collegeville, PA, United States;Respiratory Research & Development, GSK, GSK House, Brentford, Middlesex, United Kingdom;Value Evidence and Outcomes, GSK, Collegeville, PA, United States;Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, United Kingdom;

关键词: hypereosinophilic syndrome (HES);    daily symptoms;    HES-DS;    most bothersome;    patient-reported;    mepolizumab;   

DOI  :  10.3389/fmed.2023.1035250

 received in 2022-09-02, accepted in 2023-03-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundHypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage. Presentation is highly heterogenous; patients may experience symptoms affecting multiple organ systems.ObjectivesTo assess the effects of mepolizumab, which targets interleukin-5, on HES-related symptom burden, based on HES daily symptoms (HES-DS) questionnaire data collected during the Phase III (ClinicalTrials.gov ID: NCT02836496) study of mepolizumab in patients with HES.MethodsEach of the six HES-related symptoms were rated (0–10) daily by patients, recalling worst symptom experience in the prior 24 hours; change from baseline at Week 32 was also calculated for mepolizumab versus placebo.ResultsMepolizumab versus placebo reduced HES-related symptom burden severity in patients with HES at Week 32. Improvements in the median change from baseline scores were seen across all symptom groups except skin for patients treated with mepolizumab; greatest improvement from baseline was observed for breathing symptoms.ConclusionThese data highlight the considerable symptom burden associated with HES and further support the clinical benefits of mepolizumab treatment for these patients.

【 授权许可】

Unknown   
Copyright © 2023 Roufosse, Butterfield, Steinfeld, Bentley, von Maltzahn, Kwon and Nelsen.